statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn BrainStorm Cell Therapeutics Announces Management Changes as Company Plans...

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK, April...

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of...

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special...

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program BrainStorm Cell Therapeutics to Provide Update on NurOwn Program PR Newswire NEW YORK, April 8, 2024 A conference call and webcast...

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate...

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI  Get Free Report) in a research note issued on Wednesday. The brokerage set a...

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI  Get Free Report) in a research note issued to investors on Wednesday. The firm set a...

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI  Free Report) in a research report sent to investors on Monday morning. The firm issued a hold rating on...

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and...

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Volume	33,243.00
52-Wk High	$3.34
52-Wk Low	$0.134

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.07	--	--	N/A
Q4'23	-$0.11	--	--	N/A
Q3'23	-$0.15	-$0.03	80.00%	BEAT
Q2'23	-$0.15	-$0.13	10.34%	BEAT
Q1'23	-$0.17	-$0.14	15.15%	BEAT

BCLI Brainstorm Cell Therapeutics, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals